Investment advice you can actually understand
Results 1 - 10 of 771 : 1 2 3 4 5 6 7 8 9 Next
Have J&J's Approval Hopes Vanished?
Johnson & Johnson might have trouble sidestepping the competition.
Your Warning Label Is My Sales Brochure
Gilenya gets a new warning label.
This stock just hit a 52-week milestone. Where will it head from here?
This Biotech's for Sale! Reportedly.
Bloomberg reports on Amylin's potential suitors.
FDA advisory panel recommends approving rheumatoid arthritis drug tofacitinib.
Tysabri's Looking Good at a Crossroads
Sales up despite potential to lose half the patients.
Will the FDA Approve Alexza's Adasuve?
Seems unlikely, given the data.
Will Novo Nordisk Help You Retire Rich?
Stocks that give retirees what they want are incredibly valuable.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK